LLY

1,136.41

-0.5%↓

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

AZN

178.86

-2.36%↓

LLY

1,136.41

-0.5%↓

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

AZN

178.86

-2.36%↓

LLY

1,136.41

-0.5%↓

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

AZN

178.86

-2.36%↓

LLY

1,136.41

-0.5%↓

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

AZN

178.86

-2.36%↓

LLY

1,136.41

-0.5%↓

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

AZN

178.86

-2.36%↓

Kodu・Aktsiate loetelu・Johnson and Johnson
Search

Johnson and Johnson

Suletud

SektorTervishoid

238.85 0.91

Osta

Hinna uuendus 10. juuni 2026, 19:59 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

236.66

Max

240.83

Põhinäitajad

By Trading Economics

Sissetulek

119M

5.2B

Müük

-502M

24B

P/E

Sektori keskmine

25.899

49.888

Aktsiakasum

2.7

Dividenditootlus

2.31

Kasumimarginaal

21.756

Töötajad

138,200

EBITDA

182M

6.4B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+12.41% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

2.31%

2.38%

Järgmine tulemuste avaldamine

15. juuli 2026

Järgmine dividendimakse kuupäev

8. sept 2026

Turustatistika

By TradingEconomics

Turukapital

-35B

538B

Eelmine avamishind

237.94

Eelmine sulgemishind

238.85

Uudiste sentiment

By Acuity

25%

75%

51 / 344 Pingereas Healthcare

Johnson and Johnson Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. juuni 2026, 12:48 UTC

Omandamised, ülevõtmised, äriostud

Johnson & Johnson to Buy Firefly Bio for $1 Billion

DJ

Loe

24. apr 2026, 13:27 UTC

Omandamised, ülevõtmised, äriostud

Johnson & Johnson to Acquire Atraverse Medical to Bolster Cardiac Device Portfolio

DJ

Loe

8. juuni 2026, 12:04 UTC

Omandamised, ülevõtmised, äriostud

Johnson & Johnson: Firefly Acquisition Adds Proprietary Degrader Antibody Conjugate Platform >JNJ

DJ

Loe

8. juuni 2026, 12:00 UTC

Omandamised, ülevõtmised, äriostud

Johnson & Johnson To Acquire Firefly Bio for $1 Billion in Cash >JNJ

DJ

Loe

8. juuni 2026, 12:00 UTC

Omandamised, ülevõtmised, äriostud

Johnson & Johnson To Acquire Firefly Bio, Inc. To Expand Oncology Pipeline With Novel Degrader Antibody Conjugate Platform >JNJ

DJ

Loe

23. apr 2026, 21:48 UTC

Omandamised, ülevõtmised, äriostud

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

DJ

Loe

22. apr 2026, 11:27 UTC

Tulu

Intuitive Surgical Earnings Show Big Beats Don't Always Spark Stock Rallies -- Barrons.com

DJ

Loe

14. apr 2026, 19:38 UTC

Tulu

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

DJ

Loe

14. apr 2026, 14:13 UTC

Tulu

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

DJ

Loe

14. apr 2026, 12:57 UTC

Tulu

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

DJ

Loe

14. apr 2026, 11:19 UTC

Tulu

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

DJ

Loe

14. apr 2026, 10:34 UTC

Tulu

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

DJ

Loe

14. apr 2026, 10:20 UTC

Market Talk
Tulu

J&J Sees Path to Double-Digit Growth by End of Decade -- Market Talk

DJ

Loe

14. apr 2026, 10:20 UTC

Market Talk
Tulu

J&J's Tremfya Sales Continue to Surge -- Market Talk

DJ

Loe

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson: With MedTech, Anticipate Additional Rounds of VBP in China Throughout Year, Heavier in Second Half of Year >JNJ

DJ

Loe

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson: Expect Heavier Investment in First Half of 2026 Year >JNJ

DJ

Loe

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson: With Innovative Medicine, Expect More Pronounced Sales Impact From Newly Launched Products as 2026 Progresses>JNJ

DJ

Loe

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson Announce Planned Enterprise Business Review for Dec. 8, 2026 >JNJ

DJ

Loe

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson: Anticipate Higher EPS Growth in Second Half of Year Vs First Half >JNJ

DJ

Loe

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson: With MedTech, Expect Continued Acceleration of Newly Launched Products as Year Progresses With Normalized Seasonality >JNJ

DJ

Loe

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson: With MedTech, Surgery Transformation Sales Headwinds Expected to Increase Through Year >JNJ

DJ

Loe

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson Sees 2026 Adjusted Operational EPS $11.30-$11.50 Vs Prior View $11.28-$11.48 >JNJ

DJ

Loe

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson: Anticipate Fairly Consistent Operational Sales Growth in First and Second Half With 53rd Week Affecting Second Half >JNJ

DJ

Loe

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson: With Innovative Medicine, Anticipate Generic Competition for Opsumit (Second Half in U.S.) and Simponi (First Half in EU; Potentially Second Half in U. S.) >JNJ

DJ

Loe

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson Sees 2026 Adj. Operational Sales Growth in Range of 5.6%-6.6% Vs Prior View 5.4%-6.4% >JNJ

DJ

Loe

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson: 1Q Innovative Medicine Operational Sales Growth Driven Primarily by Darzalex, Carvykti, Erleada, Rybrevant/Lazcluze, Tremfya and Spravato >JNJ

DJ

Loe

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson Raises 2026 View To Sales $100.3B-$101.3B Vs Prior View $100B-$101B >JNJ

DJ

Loe

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson 1Q Orthopaedics Sales $2.38B >JNJ

DJ

Loe

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson: 1Q MedTech Business Growth Driven Primarily by Electrophysiology Products, Abiomed, Shockwave as Well as Trauma >JNJ

DJ

Loe

14. apr 2026, 10:20 UTC

Tulu

Johnson & Johnson Sees 2026 Operational Sales of $99.7B-$100.7B Vs Prior View $99.5B-$100.5B>JNJ

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Johnson and Johnson Prognoos

Hinnasiht

By TipRanks

12.41% tõus

12 kuu keskmine prognoos

Keskmine 266.4 USD  12.41%

Kõrge 285 USD

Madal 250 USD

Põhineb 17 Wall Streeti analüütiku instrumendi Johnson and Johnson 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

17 ratings

12

Osta

5

Hoia

0

Müü

Põhineb 17 analüütiku instrumendi Johnson and Johnson aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

51 / 344 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Muud aktsiad sektorist

LLY

Eli Lilly and Co.

1,136.41

↓-0.5%

ABBV

AbbVie Inc

225.29

↑ +0.05%

UNH

UnitedHealth Group Inc

407.06

↓-1.28%

MRK

Merck & Co Inc.

119

↓-0.38%

AZN

AstraZeneca PLC

178.86

↓-2.36%
help-icon Live chat